Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: sunitinib malate|OTHER: flow cytometry|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis
Sponsor: University of California, San Francisco
Collaborators: National Cancer Institute (NCI)